Primary Peritoneal Carcinoma Terminated Phase 2 Trials for Cefotaxime (DB00493)

IndicationStatusPhase
DBCOND0028874 (Primary Peritoneal Carcinoma)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00004221Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian CancerTreatment